The molecular biology of renal cell carcinoma

Seminars in Oncology

Volumn 40, Issue 4, 2013, Pages 421-428

  Keefe, Stephen M ^a   Nathanson, Katherine L ^a   Kimryn Rathmell, W ^b  

^a UNIVERSITY OF PENNSYLVANIA   (United States)

^b UNIVERSITY OF NORTH CAROLINA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

HYPOXIA INDUCIBLE FACTOR; MAMMALIAN TARGET OF RAPAMYCIN; VASCULOTROPIN; VON HIPPEL LINDAU PROTEIN;

ARTICLE; BIOENERGY; CARCINOGENESIS; CELL FATE; CHROMATIN ASSEMBLY AND DISASSEMBLY; EPIGENETICS; GENE MUTATION; GENETIC HETEROGENEITY; HISTONE METHYLATION; HISTONE MODIFICATION; HUMAN; HYPOXIA; KIDNEY CARCINOMA; METASTASIS; MOLECULAR BIOLOGY; PHENOTYPE; POINT MUTATION; PRIORITY JOURNAL; TRANSCRIPTION INITIATION; TUMOR RECURRENCE;

BASIC HELIX-LOOP-HELIX TRANSCRIPTION FACTORS; CARCINOMA, RENAL CELL; EPIGENESIS, GENETIC; HUMANS; HYPOXIA-INDUCIBLE FACTOR 1, ALPHA SUBUNIT; KIDNEY NEOPLASMS; MUTATION; TOR SERINE-THREONINE KINASES; TUMOR SUPPRESSOR PROTEINS; UBIQUITIN THIOLESTERASE; VON HIPPEL-LINDAU TUMOR SUPPRESSOR PROTEIN;

EID: 84883195289     PISSN: 00937754     EISSN: None     Source Type: Journal    
DOI: 10.1053/j.seminoncol.2013.05.006     Document Type: Article

References (76)

1. R. Siegel, D. Naishadham, and A. Jemal Cancer statistics, 2013 CA Cancer J Clin 63 1 2013 11 30
2. R.C. Flanigan, S.E. Salmon, and B.A. Blumenstein Nephrectomy followed by interferon alfa-2b compared with interferon alfa-2b alone for metastatic renal-cell cancer N Engl J Med 345 23 2001 1655 1659
3. G.H. Mickisch, A. Garin, H. van Poppel, L. de Prijck, and R. Sylvester Radical nephrectomy plus interferon-alfa-based immunotherapy compared with interferon alfa alone in metastatic renal-cell carcinoma: a randomised trial Lancet 358 9286 2001 966 970
4. T.K. Choueiri, W. Xie, and C. Kollmannsberger The impact of cytoreductive nephrectomy on survival of patients with metastatic renal cell carcinoma receiving vascular endothelial growth factor targeted therapy J Urol 185 1 2011 60 66
5. R.S. Kerbel Tumor angiogenesis N Engl J Med 358 19 2008 2039 2049
6. W.H. Chow, L.M. Dong, and S.S. Devesa Epidemiology and risk factors for kidney cancer. Nature reviews Urology 7 5 2010 245 257
7. F. Latif, K. Tory, and J. Gnarra Identification of the von Hippel-Lindau disease tumor suppressor gene Science 260 5112 1993 1317 1320
8. E.T. Collins Intra-ocular growths (two cases, brother and sister, with peculiar vascular new growth, probably retinal, affecting both eyes) Trans Ophthalmol Soc UK 14 1894 141 149
9. E. von Hippel Ueber eine sehr seltene Erkrankung der Nethaut Graefe Arch Ophthalmol 59 1904 83 106
10. A. Lindau Zur Frage der Angiomatosis Retinae und Ihrer Hirncomplikation Acta Opthalmol 4 1927 193 226
11. V.A. McKusick Mendelian inheritance in man 1992 Johns Hopkins University Press Baltimore, MD
12. B. Zbar, H. Brauch, C. Talmadge, and M. Linehan Loss of alleles of loci on the short arm of chromosome 3 in renal cell carcinoma Nature 327 6124 1987 721 724
13. B.R. Seizinger, G.A. Rouleau, and L.J. Ozelius Von Hippel-Lindau disease maps to the region of chromosome 3 associated with renal cell carcinoma Nature 332 6161 1988 268 269
14. O. Iliopoulos, A. Kibel, S. Gray, and W.G. Kaelin Jr Tumour suppression by the human von Hippel-Lindau gene product Nat Med 1 8 1995 822 826
15. C. Ricketts, E.R. Woodward, and P. Killick Germline SDHB mutations and familial renal cell carcinoma J Natl Cancer Inst 100 17 2008 1260 1262
16. E.R. Maher, H.P. Neumann, and S. Richard von Hippel-Lindau disease: a clinical and scientific review Eur J Hum Genet 19 6 2011 617 623
17. M. Ohh, C.W. Park, and M. Ivan Ubiquitination of hypoxia-inducible factor requires direct binding to the beta-domain of the von Hippel-Lindau protein Nature Cell Biol 2 7 2000 423 427
18. T. Kamura, S. Sato, K. Iwai, M. Czyzyk-Krzeska, R.C. Conaway, and J.W. Conaway Activation of HIF1alpha ubiquitination by a reconstituted von Hippel-Lindau (VHL) tumor suppressor complex Proc Natl Acad Sci U S A 97 19 2000 10430 10435
19. K. Tanimoto, Y. Makino, T. Pereira, and L. Poellinger Mechanism of regulation of the hypoxia-inducible factor-1 alpha by the von Hippel-Lindau tumor suppressor protein EMBO J 19 16 2000 4298 4309
20. M.E. Cockman, N. Masson, and D.R. Mole Hypoxia inducible factor-alpha binding and ubiquitylation by the von Hippel-Lindau tumor suppressor protein J Biol Chem 275 33 2000 25733 25741
21. W.G. Kaelin Jr Molecular basis of the VHL hereditary cancer syndrome Nat Rev Cancer 2 9 2002 673 682
22. M. Yoshida, M. Yao, and I. Ishikawa Somatic von Hippel-Lindau disease gene mutation in clear-cell renal carcinomas associated with end-stage renal disease/acquired cystic disease of the kidney Genes Chromosomes Cancer 35 4 2002 359 364
23. R.E. Banks, P. Tirukonda, and C. Taylor Genetic and epigenetic analysis of von Hippel-Lindau (VHL) gene alterations and relationship with clinical variables in sporadic renal cancer Cancer Res 66 4 2006 2000 2011
24. J.R. Gnarra, K. Tory, and Y. Weng Mutations of the VHL tumour suppressor gene in renal carcinoma Nat Genet 7 1 1994 85 90
25. H. Brauch, G. Weirich, and J. Brieger VHL alterations in human clear cell renal cell carcinoma: association with advanced tumor stage and a novel hot spot mutation Cancer Res 60 7 2000 1942 1948
26. M.L. Nickerson, E. Jaeger, and Y. Shi Improved identification of von Hippel-Lindau gene alterations in clear cell renal tumors Clin Cancer Res 14 15 2008 4726 4734
27. V.H. Haase The VHL tumor suppressor in development and disease: functional studies in mice by conditional gene targeting Semin Cell Dev Biol 16 4-5 2005 564 574
28. C.M. Lee, M.M. Hickey, and C.A. Sanford VHL type 2B gene mutation moderates HIF dosage in vitro and in vivo Oncogene 28 14 2009 1694 1705
29. K. Kondo, J. Klco, E. Nakamura, M. Lechpammer, and W.G. Kaelin Jr Inhibition of HIF is necessary for tumor suppression by the von Hippel-Lindau protein Cancer Cell 1 3 2002 237 246
30. K. Kondo, W.Y. Kim, M. Lechpammer, and W.G. Kaelin Jr Inhibition of HIF2alpha is sufficient to suppress pVHL-defective tumor growth PLoS Biol 1 3 2003 E83
31. J.D. Gordan, P. Lal, and V.R. Dondeti HIF-alpha effects on c-Myc distinguish two subtypes of sporadic VHL-deficient clear cell renal carcinoma Cancer Cell 14 6 2008 435 446
32. T. Klatte, P.N. Rao, and M. de Martino Cytogenetic profile predicts prognosis of patients with clear cell renal cell carcinoma J Clin Oncol 27 5 2009 746 753
33. N. Kroeger, T. Klatte, and K. Chamie Deletions of chromosomes 3p and 14q molecularly subclassify clear cell renal cell carcinoma Cancer 119 2013 1547 1554
34. C. Shen, R. Beroukhim, and S.E. Schumacher Genetic and functional studies implicate HIF1alpha as a 14q kidney cancer suppressor gene Cancer Disc 1 3 2011 222 235
35. M. Gerlinger, A.J. Rowan, and S. Horswell Intratumor heterogeneity and branched evolution revealed by multiregion sequencing N Engl J Med 366 10 2012 883 892
36. R.C. Osthus, H. Shim, and S. Kim Deregulation of glucose transporter 1 and glycolytic gene expression by c-Myc J Biol Chem 275 29 2000 21797 21800
37. J.W. Kim, I. Tchernyshyov, G.L. Semenza, and C.V. Dang HIF-1-mediated expression of pyruvate dehydrogenase kinase: a metabolic switch required for cellular adaptation to hypoxia Cell Metab 3 3 2006 177 185
38. G.L. Semenza HIF-1 mediates the Warburg effect in clear cell renal carcinoma J Bioenergetics Biomembranes 39 3 2007 231 234
39. A.J. Pantuck, D.B. Seligson, and T. Klatte Prognostic relevance of the mTOR pathway in renal cell carcinoma: implications for molecular patient selection for targeted therapy Cancer 109 11 2007 2257 2267
40. V.A. Robb, M. Karbowniczek, A.J. Klein-Szanto, and E.P. Henske Activation of the mTOR signaling pathway in renal clear cell carcinoma J Urol 177 1 2007 346 352
41. R. Zoncu, A. Efeyan, and D.M. Sabatini mTOR: from growth signal integration to cancer, diabetes and ageing Nat Rev Mol Cell Biol 12 1 2011 21 35
42. K. Inoki, T. Zhu, and K.L. Guan TSC2 mediates cellular energy response to control cell growth and survival Cell 115 5 2003 577 590
43. J. Brugarolas, K. Lei, and R.L. Hurley Regulation of mTOR function in response to hypoxia by REDD1 and the TSC1/TSC2 tumor suppressor complex Genes Dev 18 23 2004 2893 2904
44. J. Huang, and B.D. Manning The TSC1-TSC2 complex: a molecular switchboard controlling cell growth Biochem J. 412 2 2008 179 190
45. A.C. Gingras, B. Raught, and N. Sonenberg Regulation of translation initiation by FRAP/mTOR Genes Dev 15 7 2001 807 826
46. X.M. Ma, and J. Blenis Molecular mechanisms of mTOR-mediated translational control Nat Rev Mol Cell Biol 10 5 2009 307 318
47. M.V. Blagosklonny, and M.N. Hall Growth and aging: a common molecular mechanism Aging 1 4 2009 357 362
48. S. Wullschleger, R. Loewith, and M.N. Hall TOR signaling in growth and metabolism Cell 124 3 2006 471 484
49. B. Kucejova, S. Pena-Llopis, and T. Yamasaki Interplay between pVHL and mTORC1 pathways in clear-cell renal cell carcinoma Mol Cancer Res 9 9 2011 1255 1265
50. G. Hudes, M. Carducci, and P. Tomczak Temsirolimus, interferon alfa, or both for advanced renal-cell carcinoma N Engl J Med 356 22 2007 2271 2281
51. R.J. Motzer, B. Escudier, and S. Oudard Efficacy of everolimus in advanced renal cell carcinoma: a double-blind, randomised, placebo-controlled phase III trial Lancet 372 9637 2008 449 456
52. P.B. Crino, K.L. Nathanson, and E.P. Henske The tuberous sclerosis complex N Engl J Med 355 13 2006 1345 1356
53. E.P. Henske, H.P. Neumann, B.W. Scheithauer, E.W. Herbst, M.P. Short, and D.J. Kwiatkowski Loss of heterozygosity in the tuberous sclerosis (TSC2) region of chromosome band 16p13 occurs in sporadic as well as TSC-associated renal angiomyolipomas Genes Chromosomes Cancer 13 4 1995 295 298
54. J.B. Brugarolas, F. Vazquez, A. Reddy, W.R. Sellers, and W.G. Kaelin Jr TSC2 regulates VEGF through mTOR-dependent and -independent pathways Cancer Cell 4 2 2003 147 158
55. R.T. Abraham, and C.H. Eng Mammalian target of rapamycin as a therapeutic target in oncology Exp Opin Therapeutic Targets 12 2 2008 209 222
56. J.J. Bissler, C. Kingswood, and B.A. Zonnenberg Everolimus therapy for angiomyolipoma in patients with tuberous sclerosis complex or sporadic lymphangioleiomyomatosis: results from EXIST-2 J Clin Oncol 30 suppl 2012 abstr 356
57. N. Wolff, W. Kabbani, T. Bradley, G. Raj, L. Watumull, and J. Brugarolas Sirolimus and temsirolimus for epithelioid angiomyolipoma J Clin Oncol 28 5 2010 e65 e68
58. G. van Haaften, G.L. Dalgliesh, and H. Davies Somatic mutations of the histone H3K27 demethylase gene UTX in human cancer Nat Genet 41 5 2009 521 523
59. G.L. Dalgliesh, K. Furge, and C. Greenman Systematic sequencing of renal carcinoma reveals inactivation of histone modifying genes Nature 463 7279 2010 360 363
60. S. Wellmann, M. Bettkober, and A. Zelmer Hypoxia upregulates the histone demethylase JMJD1A via HIF-1 Biochem Biophys Res Commun 372 4 2008 892 897
61. A.J. Krieg, E.B. Rankin, D. Chan, O. Razorenova, S. Fernandez, and A.J. Giaccia Regulation of the histone demethylase JMJD1A by hypoxia-inducible factor 1 alpha enhances hypoxic gene expression and tumor growth Mol Cell Biol 30 1 2010 344 353
62. N.S. Kenneth, S. Mudie, P. van Uden, and S. Rocha SWI/SNF regulates the cellular response to hypoxia J Biol Chem 284 7 2009 4123 4131
63. J.D. Hainsworth, J.R. Infante, D.R. Spigel, E.R. Arrowsmith, R.V. Boccia, and H.A. Burris A phase II trial of panobinostat, a histone deacetylase inhibitor, in the treatment of patients with refractory metastatic renal cell carcinoma Cancer Invest 29 7 2011 451 455
64. S. Pena-Llopis, S. Vega-Rubin-de-Celis, and A. Liao BAP1 loss defines a new class of renal cell carcinoma Nat Genet 44 7 2012 751 759
65. Z.M. Eletr, and K.D. Wilkinson An emerging model for BAP1's role in regulating cell cycle progression Cell Biochem Biophysics 60 1-2 2011 3 11
66. J.W. Harbour, M.D. Onken, and E.D. Roberson Frequent mutation of BAP1 in metastasizing uveal melanomas Science 330 6009 2010 1410 1413
67. P. Kapur, S. Pena-Llopis, and A. Christie Effects on survival of BAP1 and PBRM1 mutations in sporadic clear-cell renal-cell carcinoma: a retrospective analysis with independent validation Lancet Oncol 14 2 2013 159 167
68. B. Gunawan, A. von Heydebreck, and T. Fritsch Cytogenetic and morphologic typing of 58 papillary renal cell carcinomas: evidence for a cytogenetic evolution of type 2 from type 1 tumors Cancer Res 63 19 2003 6200 6205
69. P. Gontero, G. Ceratti, and S. Guglielmetti Prognostic factors in a prospective series of papillary renal cell carcinoma BJU Int 102 6 2008 697 702
70. K. Okon, A. Sinczak-Kuta, and J. Stachura Renal papillary carcinoma classification into subtypes may be reproduced by nuclear morphometry Analytic Quantitative Cytol Histol 31 2 2009 109 117
71. A. Antonelli, R. Tardanico, and P. Balzarini Cytogenetic features, clinical significance and prognostic impact of type 1 and type 2 papillary renal cell carcinoma Cancer Genet Cytogenet 199 2 2010 128 133
72. M.L. Nickerson, M.B. Warren, and J.R. Toro Mutations in a novel gene lead to kidney tumors, lung wall defects, and benign tumors of the hair follicle in patients with the Birt-Hogg-Dube syndrome Cancer Cell 2 2 2002 157 164
73. M. Baba, S.B. Hong, and N. Sharma Folliculin encoded by the BHD gene interacts with a binding protein, FNIP1, and AMPK, and is involved in AMPK and mTOR signaling Proc Natl Acad Sci U S A 103 42 2006 15552 15557
74. M.V. Yusenko, R.P. Kuiper, T. Boethe, B. Ljungberg, A.G. van Kessel, and G. Kovacs High-resolution DNA copy number and gene expression analyses distinguish chromophobe renal cell carcinomas and renal oncocytomas BMC Cancer 9 2009 152
75. F.A. Monzon, J.M. Hagenkord, and M.A. Lyons-Weiler Whole genome SNP arrays as a potential diagnostic tool for the detection of characteristic chromosomal aberrations in renal epithelial tumors Mod Pathol 21 5 2008 599 608
76. W. Yu, W. Zhang, and Y. Jiang Clinicopathological, genetic, ultrastructural characterizations and prognostic factors of papillary renal cell carcinoma: new diagnostic and prognostic information Acta Histochem 115 2012 452 459